Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) stock jumped 1.16% on Friday to $11.35 against a previous-day closing price of $11.22. With 0.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.02 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.61 whereas the lowest price it dropped to was $11.25. The 52-week range on ZNTL shows that it touched its highest point at $31.46 and its lowest point at $9.56 during that stretch. It currently has a 1-year price target of $36.50. Beta for the stock currently stands at 1.64.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZNTL was up-trending over the past week, with a rise of 15.35%, but this was down by -36.94% over a month. Three-month performance dropped to -55.47% while six-month performance fell -56.93%. The stock lost -47.41% in the past year, while it has lost -43.64% so far this year. A look at the trailing 12-month EPS for ZNTL yields -4.63 with Next year EPS estimates of -3.77. For the next quarter, that number is -0.89. This implies an EPS growth rate of -0.07% for this year and 15.92% for next year.
Float and Shares Shorts:
At present, 70.77 million ZNTL shares are outstanding with a float of 63.53 million shares on hand for trading. On Oct 30, 2023, short shares totaled 11.14 million, which was 15.78% higher than short shares on Sep 28, 2023. In addition to Dr. Kimberly Lynn Blackwell M.D. as the firm’s CEO & Director, Mr. Cameron S. Gallagher M.B.A. serves as its Co-Founder, President & Director.
Institutional Ownership:
Through their ownership of 102.09% of ZNTL’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZNTL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZNTL analysts setting a high price target of $52.00 and a low target of $12.00, the average target price over the next 12 months is $36.50. Based on these targets, ZNTL could surge 358.15% to reach the target high and rise by 5.73% to reach the target low. Reaching the average price target will result in a growth of 221.59% from current levels.
Summary of Insider Activity:
Insiders traded ZNTL stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 5,000 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 16 over the past year. The total number of shares bought during that period was 5,560,318 while 172,759 shares were sold.
